clinical trial · NCT05605782
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
Bristol-Myers Squibb·—·active not recruiting·n = 9,000
Multiple Sclerosis, Relapsing-Remitting
brief summary
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate (S1P) receptor modulator, compared to the rates of these events in two population of participants: * Participants not exposed to ozanimod with RRMS who have received treatment with other S1P-receptor modulators disease modifying treatments (DMTs) * Participants not exposed to ozanimod with RRMS who have received treatment with other non-S1P-receptor modulators disease modifying treatments (DMTs)
started
Sep 2, 2021
primary completion
Jul 26, 2033
completion
Jul 26, 2033
last updated
Jun 26, 2025
official title
ORION (Ozanimod Real-World Safety - A Post- Authorisation Multi-National Long-term Non-Interventional Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol